Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers

Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Komé, Doba, Republic of Chad

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02895568

Enrollment

399

Registered

2016-09-09

Start date

2016-09-16

Completion date

2018-09-06

Last updated

2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasmodium Falciparum

Keywords

Antimalarial drug, Resistance, Republic of Chard

Brief summary

This study is to measure prevalence of established and candidate molecular markers of drug resistant malaria at Komé, Doba, Republic of Chad.

Detailed description

This is a cross-sectional, observational study using dried blood samples collected from P. falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT partner drugs. A maximum of 200 participants will be enrolled at each participating site per year. Study duration is 2 years. Therefore total participant is up to 400. Prospective participants will have blood collected for dried blood spot (DBS) study sample after providing informed consent. Individuals with confirmed P. falciparum infection will have DBS samples included for molecular analyses for known and candidate molecular markers of antimalarial drug resistance.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

6 Months to 75 Years

Healthy volunteers

Inclusion criteria

Participants must meet all of the inclusion criteria to participate in the study. * Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection * Written informed consent obtained

Exclusion criteria

* Patients presenting signs of severe malaria will be excluded from the survey to prevent any delay in the management of the patient.

Design outcomes

Primary

Measure	Time frame
Percent prevalence of kelch13 mutants (marker of resistance to artemisinins)	2 years

Secondary

Measure	Time frame
Percent prevalence of specimens with pfmdr1 copy number >1 (marker of resistance to mefloquine)	2 years
Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders	2 yeas

Countries

Chad

Outcome results